Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
试验速览
- 阶段
- 1 期
- 状态
- Enrolling By Invitation
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Relapse-Free Survival Rate (RFS)
研究概览
简要总结
In this open-label, randomized, prospective clinical trial, nucleophosmin-1(NPM1) mutated acute myeloid leukemia (AML) patients who have reached CR are randomized into two groups.The control group receive high-dose cytarabine(HDAC) regimen while the experimental group receive high dose of cytarabine plus tretinoin(ATRA) and arsenic trioxide(ATO) treatment.The safety and efficacy of ATRA and ATO is evaluated.
详细描述
In this open-label, randomized, prospective clinical trial, NPM1- mutated AML patients who have reached CR are randomized into two groups.
In experimental group, patients receive cytarabine at a dose of 3g/㎡/d on the first, third and fifth day, ATRA at a dose of 30mg/㎡/d on day 1-14 and ATO at a dose of 0.15mg/kg/d (maximum, 10mg/d) on day 1-14. Patients in control group only receive high dose of cytarabine.
The safety and efficacy of ATRA plus ATO regimen is evaluated.The primary outcome is relapse-free survival rate after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age of 14 to 55 years old;
- •Patients that meet the diagnostic criteria(WHO 2008 criteria) of AML (except APL subtypes) and with NPM1-mutated.
- •Reached CR after induction regimen.
- •ECOG score of ≤ 2;
- •Patients with eligible laboratory examination including liver,renal and heart function.
- •Adult patients are willing to participate in the study and sign the informed consent by themselves or by their immediate family. Patients under 18 years old willing to participate should have their legal guardians sign the informed consent.
排除标准
- •Secondary leukemia.
- •Patients had other tumor at active stage or had received radiotherapy or chemotherapy in the last 6 months due to other tumor.
- •Patients with other blood diseases(for example, haemophiliacs) are excluded.However, patients with abnormal blood count, but with undiagnosed MDS or MPD patients are included.
- •Acute panmyelosis with myelofibrosis and myeloid sarcoma patients;
- •With BCR-ABL fusion gene;
- •Pregnant or lactating women;
- •With ineligible renal or liver function;
- •With active cardiovascular disease;
- •Severe infection disease including uncured tuberculosis pulmonary aspergillosis;
- •Patients had central nervous system involvement when they were diagnosed as AML.
- •Patients with epilepsy or dementia or other mental disease who couldn't understand or follow the research.
- •Drugs, medical, mental or social situation may distract patients from following the research or being evaluated the results.
- •Patients with other factors which were considered unsuitable to participate in the study by the investigators.
研究组 & 干预措施
High Dose of Cytarabine
Patients receive high dose of cytarabine.
干预措施: Cytarabine (Drug)
HDAC + ATRA + ATO
Patients receive high dose of cytarabine plus ATRA and ATO treatment.
干预措施: Cytarabine (Drug)
HDAC + ATRA + ATO
Patients receive high dose of cytarabine plus ATRA and ATO treatment.
干预措施: all-trans retinoic acid (Drug)
HDAC + ATRA + ATO
Patients receive high dose of cytarabine plus ATRA and ATO treatment.
干预措施: Arsenic Trioxide (Drug)
结局指标
主要结局
Relapse-Free Survival Rate (RFS)
时间窗: Within 5 years after randomization
RFS is defined as the time from the date of complete remission (CR) after entry in this trial until the date of documented relapse or death for NPM1 mutated leukemia patients who achieve CR.
次要结局
- Non-relapse Mortality(through treatment completion, an average of 5 months)
- Overall Survival Rate (OS)(Within 5 years after randomization)
- Cumulative incidence of relapse(Within 5 years after randomization)